Adjuvant Chemotherapy in Older Women with High-Risk Breast Cancer: New Insights from the ASTER 70s Trial

A major phase 3 study published in The Lancet evaluates the impact of adding chemotherapy to hormonotherapy in women aged 70 and older with high-risk, hormone receptor-positive, HER2-negative breast cancer. Despite genomic indicators of high risk, the trial found no significant survival benefit from chemotherapy, while adverse events were notably higher. These findings offer important guidance on treatment decisions and risk-benefit considerations for older adults.

test

Read the full article:
https://www.sciencedirect.com/science/article/pii/S0140673625008323